摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(6-Chloronaphthalen-2-yl)sulfonyl]-4-[[5-(1-pyrrolin-2-yl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]piperazine | 763911-89-3

中文名称
——
中文别名
——
英文名称
1-[(6-Chloronaphthalen-2-yl)sulfonyl]-4-[[5-(1-pyrrolin-2-yl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]piperazine
英文别名
[4-(6-chloronaphthalen-2-yl)sulfonylpiperazin-1-yl]-[5-(3,4-dihydro-2H-pyrrol-5-yl)-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl]methanone
1-[(6-Chloronaphthalen-2-yl)sulfonyl]-4-[[5-(1-pyrrolin-2-yl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]carbonyl]piperazine化学式
CAS
763911-89-3
化学式
C26H27ClN4O3S2
mdl
——
分子量
543.11
InChiKey
HNKXVKQOLWTYOL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    36
  • 可旋转键数:
    4
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    110
  • 氢给体数:
    0
  • 氢受体数:
    6

文献信息

  • NOVEL SULFONYL DERIVATIVES
    申请人:DAIICHI PHARMACEUTICAL CO., LTD.
    公开号:EP1104754A1
    公开(公告)日:2001-06-06
    Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.
    以下是通用公式(I)所代表的磺酰衍生物:Q1-Q2-T1-Q3-SO2-QA以及含有这些衍生物的药物(其中Q1是可选择地取代的饱和或不饱和的五元或六元环烃基团,五元或六元杂环基团等;Q2是单键,,C1-C6烷基或类似物;QA是可选择地取代的芳基烃基团,杂环芳基烃基团或类似物;T1是羰基或类似物)。这些化合物具有强大的FXa抑制作用,并通过口服迅速产生令人满意且持久的抗血栓作用,因此可作为几乎不伴随副作用的抗凝血剂。
  • Novel sulfonyl derivatives
    申请人:DAIICHI PHARMACEUTICAL CO., LTD.
    公开号:US20040082611A1
    公开(公告)日:2004-04-29
    Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q 1 -Q 2 -T 1 -Q 3 -SO 2 -Q A (I) [wherein Q 1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q 2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C 1-6 alkylene group or the like; Q A represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T 1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.
    本发明描述了一种由以下式(I)表示的磺酰基衍生物: Q1-Q2-T1-Q3-SO2-QA(I) [其中,Q1表示饱和或不饱和的5-或6-环烃基、5-或6-杂环基、二环融合环或三环融合环基,可能具有取代基;Q2表示单键、原子、原子、线性或支链的C1-6烷基等;QA表示可能具有取代基的芳基基或杂芳基基;T1表示羰基基团或类似物],以及包含该化合物的药物。该化合物具有强烈的FXa抑制作用,口服后提供快速、充分和持久的抗血栓效果,并且具有低副作用,因此可用作优秀的抗凝剂。
  • US6747023B1
    申请人:——
    公开号:US6747023B1
    公开(公告)日:2004-06-08
查看更多